Pamela Kirby Net Worth

Pamela Kirby biography

Dr. Pamela J. Kirby is the Chairman of the Board at SCYNEXIS, Inc. She brings over 25 years of experience in the pharmaceutical and biotechnology industries. Dr. Kirby served as a director of Novo Nordisk A/S, a global healthcare company, from 2008 to 2011, as a member of the board of Simmons & Simmons LLP, an international law firm, from 2011 to 2013, as a director of Smith and Nephew plc (LSE: SN), a multinational medical equipment manufacturing company, from 2002 to 2014, as a director of Informa plc (LSE: INF), a multinational publishing and conference company, from 2004 to 2014, as a director of, Victrex plc (LSE: VCT), a producer of high performance polymers, since 2011, as a director of DCC plc, a diversified investments group headquartered in Ireland, she served as Director of Global Strategic Marketing and Business Development in the pharmaceutical division of Hoffmann-La Roche Ltd. From 1996 to 1998, she served as Commercial Director at British Biotech plc (now Vernalis plc). From 1979 to 1996, Dr. Kirby was with Astra AB (now AstraZeneca AB), rising through various senior management positions, being named Vice President of Corporate Strategy, Marketing and Business Development in 1994. She has a BSc in Pharmacology and a Ph.D. in Clinical Pharmacology from the University of London. Because of Dr. Kirby’s experience in senior executive positions within pharmaceutical and clinical research organizations and her extensive board experience we believe she is able to make valuable contributions to our board of directors

How old is Pamela Kirby?

Pamela Kirby is 66, he's been the Chairman of the Board of Scynexis Inc since . There are 2 older and 12 younger executives at Scynexis Inc. The oldest executive at Scynexis Inc is Patrick Langlois, 70, who is the Director.

What's Pamela Kirby's mailing address?

Pamela's mailing address filed with the SEC is C/O SCYNEXIS, INC.,, 3501 C TRICENTER BOULEVARD, DURHAM, NC, 27713.

Insiders trading at Scynexis Inc

Over the last 10 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado y Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.

What does Scynexis Inc do?

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.

Scynexis Inc executives and stock owners

Scynexis Inc executives and other stock owners filed with the SEC include:

• Dr. Marco Taglietti M.D.,
  CEO, Pres & Director
• Dr. Marco Taglietti,
  CEO, Pres & Director
• David Gonzalez Angulo,
  Chief Medical Officer
• Eric Francois,
  Chief Financial Officer
• Christine R. Coyne M.B.A.,
  Chief Commercial Officer
• Philippe Tinmouth,
  Director
• Jean-Yves Nothias,
  Director
• Guy Macdonald,
  Director
• Patrick Langlois,
  Director
• David Hastings,
  Director
• Ann Hanham,
  Director
• Steven Gilman,
  Director
• Laurent Arthaud,
  Director
• Armando Anido,
  Director
• David Angulo,
  Chief Medical Officer
• Scott Sukenick,
  General Counsel
• Nkechi Azie,
  Vice President - Clinical Development
• Jim Maffezzoli,
  Vice President of Sales and Marketing
• Eric Francois,
  Chief Financial Officer
• Marco Taglietti,
  President, Chief Executive Officer, Director
• Pamela Kirby,
  Chairman of the Board
• Debbie Etchison,
  Exec. Director of Communications
• Lawrence R. Hoffman CPA, Esq.,
  Interim CFO & Principal Accounting Officer
• Dr. Rajeshwar Motheram,
  Sr. VP of Pharmaceutical Devel. & Supply Chain
• Scott Sukenick J.D.,
  Gen. Counsel & Corp. Sec.
• Patrick Machado,
  Director
• Marion Mc Court,
  Director
• Jr. Charles F Osborne,,
  Chief Financial Officer
• Biopharma Partners Ii Lpalt...,
  
• Carole Sable,
  Chief Medical Officer
• Capital Ii Ventech,
  10% owner
• Biotechnology Fund Fcpr,
  10% owner
• Eileen Pruette,
  General Counsel
• Genavent F.C.P.R.,
  10% owner
• Mounia Chaoui,
  Director
• Edward Penhoet,
  Director
• Yves J Ribeill,
  President and CEO
• Advisors Llcperceptive Life...,
  
• Christine Coyne,
  Chief Commercial Officer
• Ivor Macleod,
  Chief Financial Officer